– Potent topical MPC inhibitors based on metabolic switch discovery reawakens Dormant hair follicle stem cells to stimulate hair growth
-PP405dDemonstrate statistically significant activation Ki67 within the hair folliclean established marker of stem cell proliferation
“Translational data from our in vitro studies on human facelift skin were further validated in a Phase 1 first-in-human clinical trial, demonstrating that PP405 effectively regenerates dormant hair follicle stem cells. “It has been proven to be revitalizing,” he said.
PP405 is a potent local mitochondrial pyruvate carrier (MPC) inhibitor that acts on cellular metabolic pathways to upregulate lactate dehydrogenase (LDH). Lactate dehydrogenase (LDH) is a enzyme to which stem cells are particularly sensitive, leading to activation and hair growth.
Data presented at AAD showed that a single topical application of 0.006% and 0.06% PP405 increased LDH activity in hair follicle stem cells within 24 hours in human facelifted skin. LDH activity coincided with a significant increase in Ki67 signal in the hair bulge, indicating a proliferative response of hair follicle stem cells. This finding demonstrated mechanistic evidence in human explanted skin, consistent with results in animal models.
This data influenced Pelage's Phase 1 clinical trial, which concluded:
“We are very excited about this data. PP405 offers a game-changing opportunity for hair loss treatment by directly targeting the hair follicle stem cells of origin through distinct mechanistic pathways.” he said.
Pelage plans to begin a multicenter Phase 2a trial of PP405 in mid-2024, recruiting both men and women with androgenetic alopecia. PP405 may also have applications in other forms of hair loss, such as telogen effluvium (stress-induced hair loss) and chemotherapy-induced hair loss.
about perage pharmaceutical
perage pharmaceutical is a clinical-stage regenerative medicine company developing new treatments for hair loss, including androgenetic alopecia and chemotherapy-induced alopecia. Focused on molecular biology and stem cell biology, Pelage advances a new class of treatments designed to reactivate dormant hair follicle stem cells and restore the body's ability to grow hair naturally. doing. Its lead program, his PP405, is currently in clinical trials. Through rigorous scientific evidence, topical formulations, and a novel mechanism of action, Pelage is pioneering a first-in-class hair growth solution for people of all hair types experiencing hair loss.
About PP405
PP405 is a novel non-invasive topical small molecule designed to reactivate dormant hair follicle stem cells and restart hair growth. This treatment focuses on addressing the metabolic processes that regulate the activation and inactivation phases of hair follicle stem cells through a regenerative medicine approach. Early results from a Phase 1 study indicate that PP405 was well tolerated and demonstrated statistically significant activation of hair follicle stem cells. In 2018, perage pharmaceutical Licensed intellectual property to PP405 and related topical small molecules. UCLA Technology Development Group.
View original content to download multimedia: https://www.prnewswire.com/news-releases/pelage-presents-late-breaking-data-at-aad-2024-meeting-demonstrated- pp405-activates-human-hair-follicle -stem cells-ex-vivo-and-in-phase-1-clinical-study-302084610.html
sauce perage pharmaceutical